These documents are partial translations of the Japanese originals for reference purposes only. In the event of any discrepancy between these translated documents.
EQS-News: Vita 34 AG / Key word(s): Annual ResultsVita 34 returns to growth path in 2023 30.04.2024 / 22:51 CET/CESTThe issuer is solely responsible for the content of this announcement.Vita 34 returns to growth path in 2023 Group revenue increases by 11.8 percent to EUR 77.1 million in challenging environment Core.
EQS-News: Vita 34 returns to growth path in 2023 finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
Vita 34 returns to growth path in 2023 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
DAICHIRONA for Intramuscular Injection is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain of the spike protein of the novel coronavirus, utilizing a.